amlodipine besylate; benazepril hydrochloride - Profile

What are the generic sources for amlodipine besylate; benazepril hydrochloride and what is the scope of patent protection?

Amlodipine besylate; benazepril hydrochloride is the generic ingredient in two branded drugs marketed by Amneal, Aurobindo Pharma Ltd, Chartwell Rx, Dr Reddys Labs Inc, Heritage, Lupin Pharms, Pharmobedient, Rising, Teva Pharms, Watson Labs, Watson Labs Inc, and Sandoz, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

There is one tentative approval for this compound.

Summary for amlodipine besylate; benazepril hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	12
NDAs:	13

Generic filers with tentative approvals for AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		10MG; 20MG	CAPSULE; ORAL
		5MG; 20MG	CAPSULE; ORAL
		5MG; 10MG	CAPSULE; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LOTREL	Capsules	amlodipine besylate; benazepril hydrochloride	5 mg/40 mg and 10 mg/40 mg	020364	1	2006-11-17
LOTREL	Capsules	amlodipine besylate; benazepril hydrochloride	2.5 mg/10 mg 5 mg/10 mg 5 mg/20 mg 10 mg/20 mg	020364	1	2004-06-09

US Patents and Regulatory Information for amlodipine besylate; benazepril hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE	amlodipine besylate; benazepril hydrochloride	CAPSULE;ORAL	077215-001	Dec 7, 2018		DISCN	No	No
Amneal	AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE	amlodipine besylate; benazepril hydrochloride	CAPSULE;ORAL	077215-002	Dec 7, 2018		DISCN	No	No
Amneal	AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE	amlodipine besylate; benazepril hydrochloride	CAPSULE;ORAL	077215-003	Dec 7, 2018		DISCN	No	No

Expired US Patents for amlodipine besylate; benazepril hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	LOTREL	amlodipine besylate; benazepril hydrochloride	CAPSULE;ORAL	020364-003	Mar 3, 1995	6,162,802
Sandoz	LOTREL	amlodipine besylate; benazepril hydrochloride	CAPSULE;ORAL	020364-002	Mar 3, 1995	4,410,520*PED
Sandoz	LOTREL	amlodipine besylate; benazepril hydrochloride	CAPSULE;ORAL	020364-006	Apr 11, 2006	6,162,802

Investment Scenario, Market Dynamics, and Financial Trajectory for Amlodipine Besylate and Benazepril Hydrochloride

Last updated: February 3, 2026

Executive Summary

Amlodipine besylate and benazepril hydrochloride are cornerstone antihypertensive agents with established roles in managing hypertension and cardiovascular risk. Combined or individual formulations command significant market share globally, driven by aging populations, increasing hypertension prevalence, and expanding healthcare access. This report provides a comprehensive analysis of their investment prospects by examining market dynamics, competitive landscape, regulatory environment, manufacturing considerations, and forecasted revenue trajectories.

---

Market Overview

Parameter	Amlodipine Besylate	Benazepril Hydrochloride
Therapeutic Class	Calcium channel blocker	ACE inhibitor
Therapeutic Indications	Hypertension, angina	Hypertension, heart failure
Global Market Size (2022)	USD 3.1 billion[1]	USD 1.2 billion[2]
CAGR (2023-2030)	4.8%	4.2%

Source: IQVIA, 2022; MarketsandMarkets, 2023

Key Market Drivers

• Aging Population: The global population aged over 60 is projected to reach 2.1 billion by 2030, escalating demand for antihypertensive medications.
• Prevalence of Hypertension: Affects approximately 1.28 billion adults worldwide[3], with projections indicating persistent growth.
• Healthcare Access & Policy: Expanded insurance coverage in emerging markets and increased focus on chronic disease management.
• Generic Entry and Pricing Dynamics: Patent expirations have led to commoditization in key markets, intensifying price competition but expanding accessible volume.

---

Market Dynamics and Trends

1. Patent Expirations and Generic Competition

Year	Amlodipine Patent Expiry	Benazepril Patent Expiry
2014	Covered in multiple jurisdictions	Similar timing in U.S. and EU
2020+	Widespread generics available

Implication: Generic proliferation has driven volumes up but compressed profit margins for branded manufacturers.

2. Formulation and Delivery Innovations

• Combination Drugs: Growing trend in fixed-dose combinations (FDCs) such as amlodipine with benazepril for improved adherence.
• Extended-Release (ER) Formulations: Offer improved dosing convenience, elevating competitive edge.

3. Regulatory and Policy Landscape

Region	Recent Regulations	Impact
U.S.	FDA's biosimilar and generics initiatives	Accelerated approval pathways, increased competition
EU	EMA's drug repurposing policies	Incentivize alternative indications and formulations

Note: Regulatory agencies focus on safety and efficacy standards, influencing R&D and marketing timelines.

---

Manufacturing and Supply Chain Considerations

Aspect	Key Points	Implication for Investors
Raw Material Sourcing	Dependence on China and India	Supply disruption risks
Manufacturing Capacity	Proprietary vs. Contracted	Flexibility and scalability advantages
Quality Control	Strict compliance with cGMP	Market access and brand trust
Logistics	Global distribution networks	Timely delivery and cost efficiency

Insight: Supply chain resilience is paramount amid geopolitical tensions and pandemic disruptions.

---

Financial Trajectory and Investment Outlook

Revenue Estimations (2023-2030)

Drug	2023 Revenue (USD billion)	Compound Annual Growth Rate (CAGR)	2030 Estimate (USD billion)
Amlodipine	3.1	4.8%	~4.4
Benazepril	1.2	4.2%	~1.6

Assumptions: Base case considering patent expirations, generic competition, and growth in emerging markets.

Profitability Trends

• Branded Drugs: Margins compressed post-generic entries (~15-20% gross profit margin).
• Generics & FDCs: Lower margins (~10-15%) but higher volume R&D focus and manufacturing scale.

Investment Risks

Risk Factor	Description	Mitigation Strategies
Regulatory Delays	Approval or market restrictions	Diversification of portfolio
Pricing Pressures	Healthcare reforms / Price caps	Optimize cost structure
Patent Litigation	Potential patent challenges	Robust patent strategy
Supply Chain	Raw material scarcity	Multi-source sourcing

---

Comparative Analysis with Competitors

Aspect	Amlodipine Market Position	Benazepril Market Position	Key Competitors	Notable Entrants
Brand-Leaders	Pfizer, Sandoz	Novartis, Teva	Various generics	Local players
Market Share (Estimated)	35-40% in generics	25-30% in generics	Multiple small/large players	Generic manufacturers

---

Conclusion: Strategic Recommendations

• Focus on FDC Formulations: Fixed-dose combinations enhance adherence and market penetration.
• Invest in Manufacturing Scalability: To capitalize on increased volume and mitigate supply risks.
• Monitor Patent Landscapes: To identify timing of generic entries and phase strategic launches accordingly.
• Expand in Emerging Markets: Demographics and increasing healthcare access provide growth avenues.
• Leverage Regulatory Trends: Engage early with authorities on new formulations and indications.

---

Key Takeaways

• The antihypertensive market, led by amlodipine and benazepril, exhibits steady growth driven by demographic trends and expanding healthcare coverage.
• Patent expirations have triggered a surge in generic competition, compressing margins but offering volume opportunities.
• Fixed-dose combinations and extended-release formulations are strategic growth segments.
• Industry is highly sensitive to regulatory changes, supply chain stability, and pricing reforms.
• Investing in manufacturing capacity, product innovation, and emerging markets positions stakeholders for long-term gains.

---

FAQs

Q1: What are the primary factors influencing the market share of amlodipine and benazepril?
A1: Key factors include patent status, generic competition, formulation innovations, regional healthcare policies, and physician prescribing behaviors.

Q2: How does the patent expiration of these drugs impact investor strategies?
A2: Patent expiration typically leads to price erosion, profit margin compression, but increased volume. Investors should monitor patent cliffs to time product launches and R&D investments effectively.

Q3: Are fixed-dose combination drugs a significant growth driver?
A3: Yes. FDCs improve treatment adherence, are preferred in polypharmacy, and often command higher market share and pricing premiums.

Q4: Which regions present the most promising opportunities for growth?
A4: Emerging markets such as Asia-Pacific and Latin America offer substantial growth prospects due to rising hypertension prevalence and expanding healthcare infrastructure.

Q5: What are the main risks associated with investing in these drugs?
A5: Risks include regulatory delays, market saturation due to generics, pricing reforms, supply chain disruptions, and increased competition from biosimilars or novel therapies.

---

References

[1] IQVIA, "Global Cardiovascular Market Report," 2022.
[2] MarketsandMarkets, "Cardiovascular Disease Treatment Market," 2023.
[3] World Health Organization, "Hypertension," 2021.